Pfizer Inc. $PFE Stake Lifted by Sanctuary Advisors LLC

Key Points

• Sanctuary Advisors increased its Pfizer stake by 4.5% in the second quarter, bringing its holdings to 1.06 million shares valued at approximately $25.5 million. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, exceeding estimates of $0.68, while revenue rose 2.6% year over year to $15.03 billion. The company maintained fiscal 2026 EPS guidance of $2.80–$3.00.
• Pfizer’s stock opened at $27.97, near its 52-week high, and the company announced a quarterly dividend of $0.43 per share, representing a 6.1% annualized yield. Analysts maintain a consensus “Hold” rating with a $28.28 price target.

Sanctuary Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,059,033 shares of the biopharmaceutical company's stock after purchasing an additional 45,358 shares during the period. Sanctuary Advisors LLC's holdings in Pfizer were worth $25,502,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in PFE. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer in the second quarter worth $26,000. HFM Investment Advisors LLC increased its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. increased its holdings in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.4%

PFE stock opened at $27.97 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a 50-day moving average of $25.34 and a two-hundred day moving average of $26.26. The stock has a market capitalization of $159.41 billion, a price-to-earnings ratio of 36.80 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $0.78 earnings per share. The firm's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. HSBC lowered shares of Pfizer from a "buy" rating to a "hold" rating and reduced their price objective for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. Finally, Weiss Ratings cut Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source